Results 141 to 150 of about 37,609 (272)
Corrigendum to “Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers” [Neurobiol. Dis. 83 (2015) 115–121]
Neurobiology of Disease, 2017 Marios Politis, Nayana Lahiri, Flavia Niccolini, Paul Su, Kit Wu, Paolo Giannetti, Rachael I. Scahill, Federico E. Turkheimer, Sarah J. Tabrizi, Paola Piccini +9 moredoaj +1 more sourcePlacebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease.
, 2011 Item does not contain fulltextBACKGROUND: Classically, clinical trials are based on the placebo-control design. Our aim was to analyze the placebo effect in Huntington's disease.Camu, W, Albanese, A, Walli, J, Meierkord, H, Gómez, Jc, Bachoud Lévi, Ac, Kwiecinski, H, Seppi, K, de Yébenes, J. G., Khoris, J, Trejo, J. M., Pages, M, Messouak, O, de Jong, D, Arguillère, S, Kowalczys, H, José María Trejo Gabriel y Galán, Ecker, D, Vingerhoets, F, Poewe, W, Cervera, C, Kuznik, D, del Puerto, I., Zarranz, Jj, Niezgoda, A, Muñoz, Je, Gawel, M, null null, Rascol, O, Przuntek, H, Zangerl, A, Andrich, J, Castillio, V, Schober, T, López, E, Kramer, B, Justo Garcia de Yébenes, Warrenburg, B.P.C. van de, Dürr, A, Sesar, A, Arconada, O. F., Autret, A, Dubois, B, Broussolle, E, Ludolph, Ac, Lukasik, M, Ochudło, S, Grimbergen, Y, Gabriel y Galàn, J. .M, Cubo, E., Inés del Puerto, Azulay, Jp, Auff, E, Viallet, F, Hannequin, D, Goizet, C, Priller, J, Alegre, J, Durif, F, Miguel González, Wider, C., Łukasik, M, Janik, P, Olga Fernández Arconada, Redondo, L, van Vugt, J, Saudeau, D, Kälin, A, Krystkowiak, P, Thibaut Tanchou, S, Foeldy, D, Jaumà, S, Bakchine, S, Landwehrmeyer, Gb, Ott, E, Tolosa, E, Gonzáles, M., Tison, F, Fanjul, S, Mateo, D, Cantarero, S, Chacón, J, Bloch, F, Kremer, H, Galitzky, M, Gámez, J, Rojo, A, Resch, F, Destée, A, Solis, P, Wenzel, K, Modestowicz, R, Esther Cubo, Świat, M, Burguera, Ja, Abbruzzese, G, Tallaksen, C, Demonet, Jf, Kremer, H.P.H., de Yébenes, Jg, FILLA, ALESSANDRO, et al., Lallement, F, Ríos, C, Burgunder, Jm, Puerto, I. del, Roos, R, Squitieri, F, Bas, J, Gamero, Ma, Guillamo, Js, Mollion, H, Pilczuk, B, Wenning, G, Engles, A, García Ruiz, P, De, J. G., Hernández, J, Gabriel y Galan, J.M., Puerto, I. d., Gonzalez, M., Lezcano, E, Dinca, L, Castro, A, Madigand, M, Dose, M, Yebenes, J.G. de, van de Warrenburg, B, Roldán, Sg, Descals, Am, Fontán, A, Saft, C, European Huntington's Disease Initiative Study Group,, Nirkko, Arto Christian, Leblhuber, F, Arconada, O.F., Memin, A, Pasquier, F, Calopa, M, Kraus, Ph, López del Val, J, Nirkko, A +141 morecore +1 more sourceThe DNA/RNA autophagy protein SIDT2 as a novel neuropathological hallmark in Huntington disease
Brain Pathology, EarlyView.SIDT2‐immunoreactive inclusions are observed in the striatum, cerebral cortex, and hypothalamus in HD cases with different Vonsattel grades, and the frequency of SIDT2‐immunoreactive inclusions is associated with longer CAG repeats in the huntingtin gene.Sanaz Gabery, Sofia Bergh, Chrisovalantou Huridou, Rachel Y. Cheong, Barbara Baldo, Paul Günther Scheunemann, Marie‐Louisa Schoebel, Linda Holmquist Mengelbier, Elisabet Englund, Catriona McLean, Carsten Saft, Deniz Kirik, Maria Björkqvist, Glenda Halliday, Elisabeth Petrasch‐Parwez, Huu Phuc Nguyen, Jonasz Jeremiasz Weber, Åsa Petersén +17 morewiley +1 more sourceThe role of glia in protein misfolding diseases
, 2010 The astrocytes, oligodendrocytes and microglia make up a significant proportion of the cells of the CNS. In recent years, there has been a burgeoning interest in the role of glial cells, in neurodegenerative disease.Samson, Bencore The role of protein arginine methyltransferases in sickle cell‐mediated neurovascular impairments in mice
British Journal of Pharmacology, EarlyView.Background and Purpose
Sickle cell disease (SCD) is a hereditary blood disorder caused by mutation of β‐globin. In SCD, haemoglobin polymerization causes red blood cells to assume a rigid sickle‐shape leading to neurovascular alterations, including development of vascular dementia – characterized by cognitive impairment and reduced cerebral perfusion ...Julia Zaccarelli‐Magalhães, Mariana Sayuri Berto Udo, Drew James Smith, Julia Langman, Luiz Henrique Matuguma, Guilherme Nagamine Gomes, Peter Rodriguez, Ammar Husan, Quanguang Zhang, Christopher G. Kevil, Cristiane Teresinha Citadin, Hung Wen Lin +11 morewiley +1 more sourceRole of funders in embedding tests in conservation practice
Conservation Biology, EarlyView.Abstract
Effective conservation practice requires decisions based on reliable and relevant evidence, but significant gaps in the evidence base exist. Incorporating well‐designed tests of the effectiveness of interventions for biodiversity in conservation projects is one of the best ways to scale up the rate of evidence generation.Rebecca K. Smith, Nancy Ockendon, Nida Al‐Fulaij, Alessandro Badalotti, Rachel Beattie, James Byrne, Sophia Cooke, Tiago de Zoeten, Winifred F. Frick, Stephan M. Funk, Douglas Gibbs, Lauren Gupta, Tatiana Hendrix, Becky Holmes, Nicola Johnstone, James Kinghorn, Simon Mickleburgh, Florence Miller, Matthew Muir, Jacob R. Owens, Danni Parks, Victoria Reilly‐Pinion, Hannah Reid, Kevin Seely, Julien Semelin, Taylor Shaw, Ruth D. Swetnam, Lisa Wheeler, William J. Sutherland +28 morewiley +1 more sourceProteostasis of organelles in aging and disease
The FEBS Journal, EarlyView.Cells rely on regulated proteostasis mechanisms to keep their internal compartments functioning properly. When these mechanisms fail, damaged proteins accumulate, disrupting organelles, such as the nucleus, mitochondria, endoplasmic reticulum, Golgi, and lysosomes, as well as membraneless organelles, such as stress granules, processing bodies, the ...Yara Nabawi, Cansu Doğan, Dunja Petrović, Gülce Perçin, Seda Koyuncu, David Vilchez +5 morewiley +1 more sourceIloperidone treatment mitigates the Juvenile Huntington's Disease phenotype possibly via Sigma‐1 Receptor Modulation
The FEBS Journal, EarlyView.We investigated the potential of iloperidone as an activator of Sigma‐1 receptor (S1R) neuroprotective function in juvenile Huntington's disease (jHD). We tested iloperidone on cortical neurons differentiated from patient‐derived iPSCs, demonstrating that it acts as a S1R agonist, decreasing apoptosis, huntingtin aggregation, and oxidative stress ...Ersilia Fornetti, Gaia Galluzzi, Mario Frezzini, Cécile Exertier, Vittorio Brufani, Gianni Colotti, Giancarlo Ruocco, Jessica Rosati, Angelo Luigi Vescovi, Daniele Narzi, Ilaria Genovese, Andrea Ilari +11 morewiley +1 more source
